Skip to main content
  • Morphometrics Predicts Overall Survival in Patients with Glioblastoma

    Final Number:

    Hesham Mostafa Zakaria MD; Richard Rammo MD; Lara Walsh Massie MD; Brent Griffith MD; Victor W. Chang MD; Ian Yu Lee MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: Predicting survival of patients with glioblastoma would help stratify treatments between aggressive to palliation. Morphometrics has been used to predict postoperative morbidity and mortality.1 This study evaluates whether morphometrics is predictive of survival in patients with glioblastoma.

    Methods: We identified patients with glioblastoma over the past two years using our internal registry. Morphometric measurements were taken of the temporalis muscle from the time of diagnosis. Overall survival and hazard ratios were calculated with multivariate cox proportional hazards regression analyses.

    Results: Of the 114 patients with GBMs included in this study, 70 (61%) were male, 93 (82%) were Caucasian, 10 (8%) were African American. The mean age at diagnosis was 63.1 years (s.d.=12.8) with a range from 21 to 88. The median survival time for all patients was 15.9 months (95%CI=13.8, 17.7). No difference was detected between males and females for average temporalis. Patients in the smallest tertile (first) for temporalis size had a shorter survival (6.7mo, 95%CI=3.6–15.7) than those in the largest (third) tertile (20.5mo, 95%CI=15.9–24.3), hazard ratio 2.32 (95%CI=1.39-3.87, p<0.001).

    Conclusions: In patients with glioblastoma, morphometric analysis of temporalis muscle size can be used to identify patients who are at risk for shorter survival. This information can be used to help with surgical and treatment decision making in this population.

    Patient Care: It provides a unique indicator for longevity in patients with glioblastoma. Morphometrics can be used to help identify patients with glioblastoma that at a high risk of decompensation and mortality.

    Learning Objectives: By the conclusion of this session, participants will be able to: 1) Describe why it is important to predict outcomes in patients with spinal metastases 2) Discuss the role of morphometrics in predicting mortality in patients with lung, breast, prostate, or myeloma spine metastases 3) Apply morphometrics to stratify high risk and low risk patients for overall survival regardless of tumor histology

    References: 1. Hasselager R, Gogenur I. Core muscle size assessed by perioperative abdominal CT scan is related to mortality, postoperative complications, and hospitalization after major abdominal surgery: a systematic review. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie. Mar 2014;399(3):287-295.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy